Michael Schemick

Part of Certara, Inc., Certara UK Holdings Ltd. is a private company that develops drug therapies. The company is based in London, UK. Certara UK Holdings was founded in 2004.

Certara Holdco, Inc. operates as holding company whose subsidiary provides decision support technology and consulting services for optimizing drug development and improving health outcomes. The company is headquartered in DE.

LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

Part of Certara, Inc., Certara UK Holdings Ltd. is a private company that develops drug therapies. The company is based in London, UK. Certara UK Holdings was founded in 2004.

XenologiQ Ltd. provides consultancy services for the drug industry. It offers services in the areas of pharmacokinetic pharmacodynamics modelling, systems pharmacology and training. The firm projects include conference presentations; dose prediction for novel biological drugs and nerve growth factor pathways systems pharmacology. The company was founded in 2011 and is headquartered in London, United Kingdom.

LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.

Certara UK Ltd. provides platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals. The company was founded by Geoffrey Thomas Tucker, Amin Rostami-Hodjegan, and John Evans on May 15, 2001 and is headquartered in London, the United Kingdom.

Part of Certara, Inc., Certara UK Holdings Ltd. is a private company that develops drug therapies. The company is based in London, UK. Certara UK Holdings was founded in 2004.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

Certara UK Ltd. provides platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals. The company was founded by Geoffrey Thomas Tucker, Amin Rostami-Hodjegan, and John Evans on May 15, 2001 and is headquartered in London, the United Kingdom.

Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.

LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.

XenologiQ Ltd. provides consultancy services for the drug industry. It offers services in the areas of pharmacokinetic pharmacodynamics modelling, systems pharmacology and training. The firm projects include conference presentations; dose prediction for novel biological drugs and nerve growth factor pathways systems pharmacology. The company was founded in 2011 and is headquartered in London, United Kingdom.

Certara UK Ltd. provides platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals. The company was founded by Geoffrey Thomas Tucker, Amin Rostami-Hodjegan, and John Evans on May 15, 2001 and is headquartered in London, the United Kingdom.